Cargando…

CDK7 is a prognostic biomarker for non-small cell lung cancer

AIM: Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related death globally despite promising progress of personalized therapy approaches. Cyclin-dependent kinase 7 (CDK7) is a kinase involved in transcription, overexpressed in a broad spectrum of cancer types and found to be...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kuempers, Christiane, Jagomast, Tobias, Heidel, Carsten, Paulsen, Finn-Ole, Bohnet, Sabine, Schierholz, Stefanie, Dreyer, Eva, Kirfel, Jutta, Perner, Sven
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9540232/ https://www.ncbi.nlm.nih.gov/pubmed/36212402 http://dx.doi.org/10.3389/fonc.2022.927140

Ejemplares similares

Delta-Like Protein 3 Expression in Paired Chemonaive and Chemorelapsed Small Cell Lung Cancer Samples
por: Kuempers, Christiane, et al.
Publicado: (2021)

CDK7 Predicts Worse Outcome in Head and Neck Squamous-Cell Cancer
por: Jagomast, Tobias, et al.
Publicado: (2022)

Prognostic Value of the New Prostate Cancer International Society of Urological Pathology Grade Groups
por: Offermann, Anne, et al.
Publicado: (2017)

PD-L1 Dependent Immunogenic Landscape in Hot Lung Adenocarcinomas Identified by Transcriptome Analysis
por: Kirfel, Jutta, et al.
Publicado: (2021)

Elevated LSD1 and SNAIL Expression Indicate Poor Prognosis in Hypopharynx Carcinoma
por: Bottner, Justus, et al.
Publicado: (2022)

NR2F6 as a Prognostic Biomarker in HNSCC
por: Klapper, Luise, et al.
Publicado: (2020)

Spatial Distribution of Immune Cells in Head and Neck Squamous Cell Carcinomas
por: Idel, Christian, et al.
Publicado: (2021)

Identification of molecular signatures associated with early relapse after complete resection of lung adenocarcinomas
por: Pasternack, Helen, et al.
Publicado: (2021)

Proteomic analyses identify HK1 and ATP5A to be overexpressed in distant metastases of lung adenocarcinomas compared to matched primary tumors
por: Pasternack, Helen, et al.
Publicado: (2023)

Expression of Prostate-Specific Membrane Antigen (PSMA) on Biopsies Is an Independent Risk Stratifier of Prostate Cancer Patients at Time of Initial Diagnosis
por: Hupe, Marie Christine, et al.
Publicado: (2018)

TRIM24 Expression as an Independent Biomarker for Prognosis and Tumor Recurrence in HNSCC
por: Klapper, Luise, et al.
Publicado: (2022)

CDK19 as a Potential HPV-Independent Biomarker for Recurrent Disease in HNSCC
por: Paulsen, Finn-Ole, et al.
Publicado: (2020)

Prognostic and immunological characteristics of CDK1 in lung adenocarcinoma: A systematic analysis
por: Du, Qingwu, et al.
Publicado: (2023)

TRIM21 Expression as a Prognostic Biomarker for Progression-Free Survival in HNSCC
por: von Bernuth, Amelie, et al.
Publicado: (2023)

CDK6 Immunophenotype Implicates Potential Therapeutic Application of CDK4/6 Inhibitors in Urothelial Carcinoma
por: Sun, Ran, et al.
Publicado: (2022)

CDK 4/6 inhibitors for the treatment of meningioma
por: Young, Jacob S., et al.
Publicado: (2022)

Case Report: Combined CDK4/6 and MEK Inhibition in Refractory CDKN2A and NRAS Mutant Melanoma
por: Forschner, Andrea, et al.
Publicado: (2021)

Synergistic Anti-Tumor Effect of Combining Selective CDK7 and BRD4 Inhibition in Neuroblastoma
por: Gao, Yang, et al.
Publicado: (2022)

Immunohistochemical Expression Analysis of Caldesmon Isoforms in Colorectal Carcinoma Reveals Interesting Correlations with Tumor Characteristics
por: Alnuaimi, Alya R., et al.
Publicado: (2023)

Targeting Mutated p53 Dependency in Triple-Negative Breast Cancer Cells Through CDK7 Inhibition
por: Peng, Jingyu, et al.
Publicado: (2021)

Mechanisms and Implications of CDK4/6 Inhibitors for the Treatment of NSCLC
por: Zhang, Jinmeng, et al.
Publicado: (2021)

CDK4/6 inhibitor resistance: A bibliometric analysis
por: Pang, Jiayuecheng, et al.
Publicado: (2022)

Systematic evaluation and optimization of protein extraction parameters in diagnostic FFPE specimens
por: Dressler, Franz F., et al.
Publicado: (2022)

CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors
por: Schettini, Francesco, et al.
Publicado: (2018)

Clinical and Pharmacologic Differences of CDK4/6 Inhibitors in Breast Cancer
por: George, Mridula A., et al.
Publicado: (2021)

CDK4: A Novel Therapeutic Target for Extramammary Paget’s Disease
por: Hashimoto, Hiroki, et al.
Publicado: (2021)

CDK7 Inhibitor THZ1 Induces the Cell Apoptosis of B-Cell Acute Lymphocytic Leukemia by Perturbing Cellular Metabolism
por: Abudureheman, Tuersunayi, et al.
Publicado: (2021)

GC1qR Cleavage by Caspase-1 Drives Aerobic Glycolysis in Tumor Cells
por: Sünderhauf, Annika, et al.
Publicado: (2020)

CDK10 in Gastrointestinal Cancers: Dual Roles as a Tumor Suppressor and Oncogene
por: Bazzi, Zainab A., et al.
Publicado: (2021)

CDK4/6 and PDGFRA Signaling as Therapeutic Targets in Diffuse Intrinsic Pontine Glioma
por: Hoeman, Christine, et al.
Publicado: (2018)

A Splice Site Variant of CDK12 and Breast Cancer in Three Eurasian Populations
por: Bogdanova, Natalia V., et al.
Publicado: (2019)

Mechanisms of Resistance to CDK4/6 Inhibitors: Potential Implications and Biomarkers for Clinical Practice
por: McCartney, Amelia, et al.
Publicado: (2019)

CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells
por: Digiacomo, Graziana, et al.
Publicado: (2022)

NOL6 Regulates the Proliferation and Apoptosis of Gastric Cancer Cells via Regulating TP53I3, CDK4 and MCM7 Expression
por: He, Lei, et al.
Publicado: (2022)

Roles of JAK2 in Aging, Inflammation, Hematopoiesis and Malignant Transformation
por: Perner, Florian, et al.
Publicado: (2019)

CDK4/6 Inhibitor PD0332991 in Glioblastoma Treatment: Does It Have a Future?
por: Schröder, Lisette B. W., et al.
Publicado: (2015)

In silico analysis reveals EP300 as a panCancer inhibitor of anti-tumor immune response via metabolic modulation
por: Krupar, Rosemarie, et al.
Publicado: (2020)

CDK3, CDK5 and CDK8 Proteins as Prognostic and Potential Biomarkers in Colorectal Cancer Patients
por: Wang, Dan, et al.
Publicado: (2022)

PKM2 Interacts With the Cdk1-CyclinB Complex to Facilitate Cell Cycle Progression in Gliomas
por: Ohba, Shigeo, et al.
Publicado: (2022)

CDK4/6 Inhibitors in Combination Therapies: Better in Company Than Alone: A Mini Review
por: Rampioni Vinciguerra, Gian Luca, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_255dp08tu3hb12as1bnochsokc